Oncogenic Mutants of MEK1: A Trilogy Unfolds

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MEK (Mitogen-activated protein kinase kinase) mutations are common in various cancers.
• It was previously assumed that all MEK mutants behave similarly and respond uniformly to targeted therapies.
• RAF dependency has been a key factor in predicting response to MEK inhibitors.

Purpose of the Study:

• To challenge the assumption of uniform MEK mutant behavior and drug response.
• To classify MEK1 mutants based on their RAF dependency.
• To identify novel therapeutic strategies for MEK-mutant cancers.

Main Methods:

• Phenotypic classification of MEK1 mutants.
• Assessment of RAF dependency in different MEK1 mutant classes.
• Testing sensitivity to allosteric and ATP-competitive MEK inhibitors.

Main Results:

• MEK1 mutants were categorized into three distinct phenotypic classes based on RAF dependency.
• A novel class of MEK1 mutants was identified as RAF-independent.
• This RAF-independent class demonstrated resistance to conventional allosteric MEK inhibitors.
• The RAF-independent MEK1 mutants showed sensitivity to a new ATP-competitive MEK inhibitor.

Conclusions:

• MEK1 mutants exhibit diverse functional behaviors and drug responses.
• RAF independence defines a new, therapeutically relevant subclass of MEK1 mutants.
• Targeting MEK1 via ATP-competitive inhibition offers a promising strategy for RAF-independent, MEK-mutant cancers.